Abstract: The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds.
Type:
Grant
Filed:
April 10, 2023
Date of Patent:
April 30, 2024
Assignee:
GC Cell Corporation
Inventors:
Jong Seo Lee, Kyu Tae Kim, Young Ha Lee, In Sik Hwang, Bong Kook Ko, Eunji Choi, You-Sun Kim, Jeongmin Kim, Miyoung Jung, Hoyong Lim, Sungyoo Cho
Abstract: Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.
Type:
Grant
Filed:
February 24, 2021
Date of Patent:
April 23, 2024
Assignee:
Zymeworks BC Inc.
Inventors:
Nina E. Weisser, Gordon Yiu Kon Ng, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
Abstract: The present disclosure relates generally to antibody-drug conjugates comprising monoclonal antibodies that specifically bind the human B7-H4 in soluble form, or membrane bound (i.e., when expressed on a cell surface) and to methods of using these conjugates as therapeutics and/or diagnostics.
Type:
Grant
Filed:
January 4, 2022
Date of Patent:
April 23, 2024
Assignee:
Mersana Therapeutics, Inc.
Inventors:
Timothy B. Lowinger, Chen-Ni Chin, Marc I. Damelin, Dorin Toader
Abstract: The present disclosure provides methods of treating or inhibiting cancer pain in a patient in need thereof, including selecting a patient with cancer, and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor. The present disclosure also provides methods of reducing analgesic use in a patient in need thereof, including selecting a patient with cancer, and administering to the patient a therapeutically effective amount of a PD-1 inhibitor, wherein the patient is being treated with background analgesic therapy prior to administration of the PD-1 inhibitor. In some embodiments, the disclosed methods concurrently lead to tumor regression, pain reduction, and reduced use of analgesic therapy.
Abstract: Provided herein are novel antigen binding domains and antibodies (e.g., heterodimeric antibodies) that bind Prostate Specific Membrane Antigen (PSMA). In exemplary embodiments, the anti-PSMA antibodies also bind CD3. Such antibodies that bind PSMA and CD3 are useful, for example in the treatment of PSMA-related cancer.
Type:
Grant
Filed:
May 14, 2021
Date of Patent:
March 5, 2024
Assignee:
Xencor, Inc.
Inventors:
John R. Desjarlais, Alex Nisthal, Michael Hedvat, Matthew Adam Dragovich
Abstract: Provided herein are methods of treating a nonhematopoietic malignant tumor in a patient and methods of prognosing a nonhematopoietic malignant tumor in a patient, comprising administering to the patient a therapeutically effective amount of an agent that preferentially kills or inhibits proliferation or activity of leukocytes relative to nonhematopoietic cells.
Type:
Grant
Filed:
March 19, 2021
Date of Patent:
February 27, 2024
Assignee:
Memorial Sloan Kettering Cancer Center
Inventors:
Larry Norton, Ross Levine, Maria Kleppe, Elizabeth Comen
Abstract: The present invention relates, in part, to agents that bind fibroblast activation protein (FAP) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the FAP binding agents and their use in the treatment of various diseases.
Type:
Grant
Filed:
February 5, 2019
Date of Patent:
February 13, 2024
Assignee:
Orionis Biosciences, Inc.
Inventors:
Nikolai Kley, Jan Tavernier, Anje Cauwels
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MerTK polypeptide, e.g., a mammalian MerTK or human MerTK, and use of such compositions in treating an individual in need thereof.
Abstract: There are provided, inter alia, compositions and methods for treatment of chemoresistant cancer (breast cancer). The methods include administering to a subject in need a therapeutically effective amount of a chemotherapeutic agent and a ROR-1 antagonist. Further provided are pharmaceutical compositions including chemotherapeutic agent, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the chemotherapeutic agent is paclitaxel and the ROR-1 antagonist is cirmtuzumab.
Type:
Grant
Filed:
March 11, 2019
Date of Patent:
January 30, 2024
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Thomas Kipps, Suping Zhang, Emanuela M. Ghia
Abstract: The present disclosure describes significant methylation changes in multiple genes and multiple metabolites in body fluid in response to TBI. Gene pathways affected included several known to be involved in neurological and brain function. A large number of good to excellent biomarkers for the detection of TBI was identified. The combination of epigenomic, clinical and metabolomic markers in different combinations overall were highly accurate for the detection of pediatric concussion using Artificial Intelligence-based techniques.
Abstract: The present invention provides methods and compositions comprising a particle comprising at least two different targeting agents that each bind a different protein receptor on a T cell surface.
Type:
Grant
Filed:
March 28, 2018
Date of Patent:
January 30, 2024
Assignee:
The University of North Carolina at Chapel Hill
Abstract: Given a set of therapeutic epitopes, a cassette sequence is designed to reduce the likelihood that junction epitopes are presented in the patient. The cassette sequence is designed by taking into account presentation of junction epitopes that span the junction between a pair of therapeutic epitopes in the cassette. The cassette sequence may be designed based on a set of distance metrics each associated with a junction of the cassette. The distance metric may specify a likelihood that one or more of the junction epitopes spanning between a pair of adjacent epitopes will be presented.
Type:
Grant
Filed:
November 21, 2018
Date of Patent:
January 30, 2024
Assignee:
Gritstone bio, Inc.
Inventors:
Brendan Bulik-Sullivan, Thomas Francis Boucher, Roman Yelensky, Jennifer Busby
Abstract: The present invention relates to combination therapies with bispecific anti-EGFR/c-Met antibodies and 3rd generation EGFR tyrosine kinase inhibitors.
Type:
Grant
Filed:
May 14, 2020
Date of Patent:
January 23, 2024
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Sylvie Laquerre, Matthew Lorenzi, Sheri Moores
Abstract: Disclosed herein are methods of diagnosing and treating MYC-driven cancers by detecting a PVT1 splice variant in a biological sample from a subject.
Type:
Grant
Filed:
May 8, 2019
Date of Patent:
January 9, 2024
Assignee:
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Abstract: Provided herein are, inter alia, humanized 1E9 antibodies capable of binding CD73. The humanized antibodies are useful for the treatment of cancer. Further provided are nucleic acids encoding humanized 1E9 antibodies and methods of inhibiting cell proliferation using the humanized antibodies provided herein.
Type:
Grant
Filed:
September 24, 2020
Date of Patent:
January 2, 2024
Assignees:
CORVUS PHARMACEUTICALS, INC., BIOATLA, INC.
Inventors:
Emily Piccione Griffin, Richard A. Miller, Gerhard Johann Frey, Hwai Wen Chang
Abstract: Disclosed herein are to markers, methods and systems for identifying cell populations, diagnosing, monitoring and treating cancer, including biomarkers predictive of response to immunotherapy treatment in Merkel cell carcinoma.
Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.
Type:
Grant
Filed:
June 18, 2021
Date of Patent:
January 2, 2024
Assignee:
GO Therapeutics, Inc.
Inventors:
Hans H. Wandall, Johannes Wirenfeldt Vad Pedersen, Eric Paul Bennett, Henrik Clausen, Ulla Mandel
Abstract: Methods for diagnosis or prognosis of a cancer in a subject are provided and include the steps of: obtaining a biological sample from a subject; determining an amount of a phosphorylation at a Y260 residue in a Na/K ATPase present in the biological sample; and comparing the amount of the phosphorylation in the sample to a control level to thereby diagnose the cancer. Methods for detecting a metabolic switch from oxidative phosphorylation to aerobic glycolysis are also provided in which a biological sample including one or more cells is obtained and an amount of a phosphorylation at a Y260 residue in a Na/K ATPase is determined in the one or more cells.
Type:
Grant
Filed:
September 6, 2018
Date of Patent:
December 19, 2023
Assignee:
MARSHALL UNIVERSITY RESEARCH CORPORATION
Abstract: A polypeptide complex comprises antibody variable regions of the heavy chain and light chain respectively fused to TCR constant regions. A bispecific antigen binding polypeptide complex contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety. A method comprises producing the polypeptide complex or the bispecific antigen binding polypeptide complex. A method of treating disease or disorder comprises using the polypeptide complex or the bispecific antigen binding polypeptide complex. A polynucleotide encodes the polypeptide complex and/or the bispecific antigen binding polypeptide complex. A vector or a host cell contains the polynucleotide. A composition and a pharmaceutical composition comprise the polypeptide complex and/or the bispecific antigen binding polypeptide complex.